TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.
Clarity Pharmaceuticals has signed a supply agreement with The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology for copper-64, which will support multiple clinical trials and pre-clinical programs. This agreement enhances Clarity’s capacity to provide innovative diagnostic options for prostate cancer and supports the development of theranostic programs, reflecting the company’s commitment to advancing cancer treatment and strengthening its collaborations within the Australian scientific community.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes for both children and adults. The company is engaged in creating advanced diagnostic and therapeutic agents, particularly for prostate cancer, and is actively involved in research and development collaborations, including participation in the Australian Research Council Hub for Advanced Manufacture of Targeted Radiopharmaceuticals.
YTD Price Performance: -14.63%
Average Trading Volume: 1,689,817
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$1.14B
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.